B2BROKER
18.4.2024 18:07:28 CEST | Business Wire | Press release
Leading Prime of Prime liquidity provider B2Broker is committed to quality, always listening to their clients' needs to provide them with the best possible tools to bring in more end users and gain a competitive edge in the industry. In this regard, B2Broker announces the rise of the leverage to 1:200 for major FX pairs, thereby reducing the margin requirements from 1% to 0.5%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418556608/en/
B2Broker increases leverage on major FOREX pairs to 1:200 and to 1:50 for BTC/USD and ETH/USD pairs, enhancing the market position of their clients. (Graphic: Business Wire)
Additionally, with the cryptocurrency market thriving and traders’ demands for higher leverage growing, the company has increased leverage up to 1:50 for BTCUSD and ETHUSD, reducing margin requirements from 10% to 2% and significantly enhancing the clients' market position.
Additional Information about B2Broker Liquidity Solutions
Having been in the industry for over a decade, B2Broker's liquidity solutions have significantly expanded. They currently offer over 1500 instruments across 8 asset classes, including FOREX, Crypto CFD, Spot Indices, Precious Metals, Single Stocks, ETFs, Commodities, and NDFs CFD.
B2Broker ensures access to deep liquidity pools from Tier-1 providers, facilitating tight spreads and ultra-fast execution. Advanced technology platforms and FIX API integrations like B2Trader, cTrader, oneZero, Prime XM, Centroid, TFB, TradeLocker, Your Bourse, FX Cubic, and MT4/MT5 allow for seamless connectivity across multiple trading systems. The infrastructure of B2Broker facilitates the distribution and aggregation of liquidity through various channels, enhancing trade execution and reducing risk.
The key strengths of the liquidity solutions include a robust infrastructure, extensive connectivity options, and the ability to develop customised liquidity setups to meet the client’s demands.
As an industry leader, B2Broker has introduced multiple innovative solutions throughout its journey. Last year, the company introduced NDFs as a new asset class in the form of CFDs, with the advantage of next-day settlements. Furthermore, they were the first in the market to introduce crypto CFDs based on spot and then perpetual futures LPs. And now, B2Broker proudly offers the most competitive margin conditions on the market!
The company has significantly strengthened its balance sheet by serving over 250 institutional clients and 30 professional funds. Because of this strong financial base, it has been able to expand leverage and meet clients' requests.
With the increased leverage on highly demanded trading pairs in key markets such as FX and Crypto, the company empowers brokers to give their traders greater flexibility in managing their capital, significantly broadening the client’s appeal to a larger user base.
John Murillo, Chief Dealing Officer of B2Broker Group of Companies, remarked:
“This strategic update not only enhances our clients' competitive edge but also augments their capacity to cater to the evolving demands of their clientele, attract new business, and elevate their service standards by leveraging our liquidity solutions.
Thanks to our robust balance sheet and extensive client base, coupled with our impressive trading volumes, we stand at the forefront of the market. Our innovative mindset has been evident throughout our journey. We were the first to introduce crypto CFDs based on spot and, later, on perpetual futures. In addition to FOREX, today, we proudly offer over 150 crypto CFD pairs, a testament to our commitment to innovation and meeting the diverse needs of our clients.”
Final Remarks
B2Broker is a distinguished leader in the FinTech sector, revolutionising the industry with significant contributions over the last decade. With a dedication to innovation and continuous improvement, the company guarantees that its clients stay ahead of the competition and set trends alongside it. Their vast ecosystem provides solutions that suit various business models.
In the latest update, B2Broker has substantially upgraded the leverage to provide the most competitive conditions for institutional clients, professional traders, brokerages, hedge funds, proprietary trading desks, and other financial institutions.
Contact B2Broker today for tailored solutions that drive success!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418556608/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom